What is the primary treatment used for managing Myasthenia Gravis?

The primary treatment for managing Myasthenia Gravis is pyridostigmine. This medication is an acetylcholinesterase inhibitor, which works by preventing the breakdown of acetylcholine in the neuromuscular junction. By increasing the availability of acetylcholine, pyridostigmine enhances communication between nerves and muscles, thereby improving muscle strength and alleviating the symptoms of Myasthenia Gravis.

While corticosteroids and immunosuppressants like azathioprine are important for managing more severe cases or for long-term treatment to reduce the autoimmune response, pyridostigmine is often the first-line therapy due to its direct mechanism of action in enhancing neuromuscular transmission. Intravenous immunoglobulin can be effective in acute exacerbations or in crisis situations, but it is not used as a primary treatment for long-term management. Thus, pyridostigmine's role is pivotal in symptomatic treatment and is considered the cornerstone of therapy for patients diagnosed with this condition.